Comparative Pharmacology
Head-to-head clinical analysis: DOXERCALCIFEROL versus ZEMPLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXERCALCIFEROL versus ZEMPLAR.
DOXERCALCIFEROL vs ZEMPLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxercalciferol is a synthetic vitamin D2 analog that undergoes hepatic conversion to its active metabolite, 1α,25-dihydroxyvitamin D2, which binds to the vitamin D receptor (VDR) in the parathyroid glands, reducing parathyroid hormone (PTH) synthesis and secretion. It also increases intestinal calcium and phosphate absorption and promotes bone mineralization.
Vitamin D receptor agonist; binds to vitamin D receptors, regulating gene expression of calcium-binding proteins and cellular proliferation/differentiation.
0.5 mcg orally three times per week at each hemodialysis session; alternatively, 1 mcg orally three times per week. Intravenous: 0.5 mcg bolus three times per week at end of hemodialysis; titrate to target intact parathyroid hormone (iPTH) level.
0.04-0.1 mcg/kg IV three times weekly; titrate to serum calcium. Oral: 1-2 mcg daily or 0.5-1 mcg three times weekly.
None Documented
None Documented
Clinical Note
moderateDoxercalciferol + Hydrochlorothiazide
"Doxercalciferol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateDoxercalciferol + Bendroflumethiazide
"Doxercalciferol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateDoxercalciferol + Methyclothiazide
"Doxercalciferol may increase the hypercalcemic activities of Methyclothiazide."
Clinical Note
moderateDoxercalciferol + Hydroflumethiazide
Terminal elimination half-life is approximately 96 hours (range 48–168 hours) in patients with chronic kidney disease, reflecting slow release from adipose tissue and prolonged vitamin D receptor activation.
Terminal elimination half-life is 5–7 hours in healthy subjects; prolonged to 14–21 hours in patients with chronic kidney disease stage 5 on hemodialysis, reflecting reduced clearance.
Primarily fecal (biliary) elimination; renal excretion accounts for <2% of unchanged drug in urine.
Primarily hepatobiliary (74% of absorbed dose recovered in feces as parent drug and metabolites); renal excretion accounts for approximately 16% (primarily as metabolites).
Category A/B
Category C
Vitamin D Analog
Vitamin D Analog
"Doxercalciferol may increase the hypercalcemic activities of Hydroflumethiazide."